Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating activities
Net income	$ 1,515	$ 1,623
Adjustments to reconcile net income to net cash provided by/(used in) operating activities:
Depreciation and amortization	194	111
Noncash lease expense	34	32
Stock-based compensation	241	176
Deferred income tax expense (benefit)	15	(41)
Contingent consideration fair value adjustments	96	(7)
Other investment (gains)	(36)	(24)
Net (gains) losses within CIPs	(13)	(104)
Net (purchases) proceeds within CIPs	(1,098)	(989)
(Earnings) losses from equity method investees	(51)	(48)
Distributions of earnings from equity method investees	14	8
Changes in operating assets and liabilities:
Accounts receivable	123	(73)
Investments, trading	12	(9)
Other assets	(3,454)	(796)
Accrued compensation and benefits	(1,794)	(1,339)
Accounts payable and accrued liabilities	84	196
Other liabilities	2,990	876
Net cash provided by/(used in) operating activities	(1,128)	(408)
Investing activities
Purchases of investments	(298)	(324)
Proceeds from sales and maturities of investments	151	210
Distributions of capital from equity method investees	13	162
Net consolidations (deconsolidations) of sponsored investment funds	(1)	(6)
Acquisition, net of cash acquired	(3,123)	0
Purchases of property and equipment	(78)	(64)
Net cash provided by/(used in) investing activities	(3,336)	(22)
Financing activities
Repayments of long-term borrowings	0	(1,000)
Proceeds from long-term borrowings	0	2,979
Cash dividends paid	(838)	(795)
Proceeds from stock options exercised	51	144
Repurchases of common stock	(657)	(634)
Net proceeds from (repayments of) borrowings by CIPs	(24)	(14)
Net subscriptions received/(redemptions/distributions paid) from noncontrolling interest holders	811	430
Other financing activities	(4)	(15)
Net cash provided by/(used in) financing activities	(661)	1,095
Effect of exchange rate changes on cash, cash equivalents and restricted cash	110	(27)
Net increase/(decrease) in cash, cash equivalents and restricted cash	(5,015)	638
Cash, cash equivalents and restricted cash, beginning of period	12,779	8,753
Cash, cash equivalents and restricted cash, end of period	7,764	9,391
Supplemental schedule of noncash investing and financing transactions:
Issuance of common stock	0	392
Increase (decrease) in noncontrolling interests due to net consolidation (deconsolidation) of sponsored investment funds	$ (522)	$ (353)